BlackRock Inc. increased its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 7.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,926,265 shares of the biopharmaceutical company’s stock after acquiring an additional 1,298,185 shares during the quarter. BlackRock Inc. owned approximately 8.93% of Alexion Pharmaceuticals worth $2,424,428,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in Alexion Pharmaceuticals by 3.1% during the 1st quarter. Vanguard Group Inc. now owns 14,467,456 shares of the biopharmaceutical company’s stock worth $1,754,034,000 after acquiring an additional 433,293 shares during the last quarter. State Street Corp grew its position in Alexion Pharmaceuticals by 6.8% during the 1st quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock worth $1,369,846,000 after acquiring an additional 718,756 shares during the last quarter. Ameriprise Financial Inc. grew its position in Alexion Pharmaceuticals by 0.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 6,175,296 shares of the biopharmaceutical company’s stock worth $751,363,000 after acquiring an additional 25,724 shares during the last quarter. Bank of New York Mellon Corp grew its position in Alexion Pharmaceuticals by 2.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,349,821 shares of the biopharmaceutical company’s stock worth $407,573,000 after acquiring an additional 64,800 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its position in Alexion Pharmaceuticals by 42.2% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 3,219,961 shares of the biopharmaceutical company’s stock worth $391,773,000 after acquiring an additional 955,578 shares during the last quarter. Institutional investors and hedge funds own 94.26% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) traded down 0.65% on Thursday, reaching $145.51. The company’s stock had a trading volume of 534,793 shares. The firm has a 50-day moving average price of $137.59 and a 200 day moving average price of $124.34. The firm has a market capitalization of $32.48 billion, a PE ratio of 63.10 and a beta of 1.40. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. The company had revenue of $912.00 million during the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. Alexion Pharmaceuticals’s revenue was up 21.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.13 earnings per share. On average, analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.61 earnings per share for the current fiscal year.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the sale, the director now owns 5,480 shares in the company, valued at $799,038.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Julie O’neill sold 4,375 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total value of $636,300.00. Following the sale, the executive vice president now owns 26,092 shares of the company’s stock, valued at approximately $3,794,820.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,070 shares of company stock valued at $2,416,869. 4.35% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This piece was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/09/14/blackrock-inc-buys-1298185-shares-of-alexion-pharmaceuticals-inc-alxn.html.

Several research firms recently issued reports on ALXN. Stifel Nicolaus restated a “buy” rating and set a $157.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Jefferies Group LLC set a $120.00 price target on Alexion Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, June 8th. UBS AG reiterated a “buy” rating and issued a $140.00 price objective (down previously from $143.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, May 31st. BMO Capital Markets reiterated an “outperform” rating and issued a $173.00 price objective (up previously from $168.00) on shares of Alexion Pharmaceuticals in a report on Wednesday. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a $158.00 price objective (up previously from $153.00) on shares of Alexion Pharmaceuticals in a report on Wednesday. Five research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and three have given a strong buy rating to the stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average price target of $157.74.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.